Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause mortality than dipeptidyl peptidase-4 inhibitor ...

University of Pennsylvania and Syracuse University scientists have discovered that a hindbrain-derived peptide, octadecaneuropeptide (ODN), can suppress appetite and improve glucose regulation without ...

The obesity epidemic has significantly heightened the impact of cardiometabolic risk factors on the global burden of cardiovascular and kidney diseases. Glucagon-like peptide-1 receptor agonists ...

1. In this population-based cohort study, patients with type 2 diabetes who received glucagon-like peptide-1 receptor agonists had a higher risk of developing gastroesophageal reflux disease and ...

Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...

Background: With the widespread use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in managing diabetes and obesity, the occurrence of GLP-1 RA-induced cholecystitis and cholelithiasis has ...

Ecnoglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist analogue, similar to the blockbuster obesity drug semaglutide.

Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034 with Focus on Semaglutide, Dulaglutide, Exenatide, Liraglutide, Tirzepatide, Lixisenatide - ResearchAndMarkets.com ...